Innovative Approache in Treating Acne Vulgaris: a Literature Review
Date Issued | Start Page | End Page |
---|---|---|
2024-04-11 | 71 | 72 |
Abstract no. 39
Introduction Acne Vulgaris induces inflammation, scarring [1]. Three forms of Botulinum neurotoxin A (BTX-A): OnaBTX-A, AboBTX-A, IncoBTX-A, aids in acne, scarring by blocking acetylcholine, reducing sebum, intercepting microbiome changes, halting follicular keratinization [2]. However, BTX-A higher cost warrants evaluation of benefits versus drawbacks [3]. Aim To analysed scientific studies on BTX-A's use in acne vulgaris treatment, side effects, and long-term application. Methods and Materials Systematic literature review performed following the PRISMA guidelines, using the Pubmed database from January to February 2024. Keywords: botulinum neurotoxin, acne vulgaris, facial pores, sebum, hyperpigmentation. Inclusion criteria: full text articles, in english, published within the last 10 years, presenting the response to the applied treatment. Excluded: case reports, literature, systematic reviews, meta-analyses. Out of 78 articles 11 were selected. Discussion For facial pores treatment (n=87), IncoBTX-A/OnoBTX-A were intradermally injected to the forehead, cheeks, average total dose (ATD) - 42 U, average focal dose (AFD) - 4 U [4-7]. Pore quantity decreased by 42%, size by 63%, effects lasting 4 months. 20% experienced temporary redness, burning. For sebum hypersecretion (n=134), OnaBTX-A/AboBTX-A were injected (ATD - 20 U, AFD - 2,5 U) to cheeks, chin, affects lasting 5 months [5] [8-10]. 1 reporting temporary mouth lift issues. For acne lesions (n=80), IncoBTX-A/OnaBTX-A were injected (ATD - 20 U, AFD - 2 U) to cheeks, chin, forehead [11-12]. Lesions decreased by 21%. Effects lasted 4 months. For acne scars, hyperpigmentation (n=82), OnaBTX-A/AboBTX-A/IncoBTX-A were injected (ATD - 20 U, AFD - 3 U) to cheeks, forehead with 34% optimal, 30% satisfactory improvement. No adverse reactions, long-term efficacy monitored [6] [13-14]. Conclusion OnaBTX-A/IncoBTX-A - the most favourable options for acne vulgaris, influencing every phase of acne development. Despite the absence of long-term adverse effects, BTX-A efficacy typically lasts 4 months, a factor that might not warrant the expense for all patients.